Friday, September 16, 2022

• All program times are EDT (New York City time)
• Check out our online auction, www.thyca.org/auction
• Your feedback is important! Please fill out the session evaluation survey at the end of each session.

9:30 – 10:30 a.m. EDT
101 Roundtable: If you’re new to thyroid cancer – things to know and questions to ask.
   Barb Allhoff, ThyCa Volunteer. [N]
102 Roundtable: If this is your first conference – things to know and questions to ask.
   Abby Melendez, ThyCa Volunteer. [All]
103 Get “schooled”: Educational accommodations and advocacy for children diagnosed with thyroid cancer. Pam Mendenhall, LISW, ThyCa Pediatric Support Moderator. [Ped]
104 Update on the management of anaplastic thyroid cancer.
   Maria E. Cabanillas, MD, Oncologic Endocrinologist. [A,SR]
105 Caregivers roundtable. Miguel Melendez, ThyCa Volunteer.

10:40 – 10:50 a.m. EDT
116 Welcome and announcements.
   Gary Bloom, ThyCa Executive Director; and Howard Solomon, ThyCa Board Chair.

11:00 a.m. – 12:30 p.m. EDT
121 Getting to know each other: Open-microphone roundtables. ThyCa Volunteers. [All]
122 Poorly differentiated thyroid cancer roundtable: Getting to know each other.
   Julie Martwick, ThyCa Volunteer. [Adv,PF]
123 Medullary thyroid cancer roundtable: Getting to know each other – Part 1. Bill McClain and Kelley Pratt, ThyCa Volunteers. [M]
124 Anaplastic thyroid cancer roundtable: Getting to know each other.
   Cheri Lindle, MEd; and Patti Turner, ThyCa Volunteers. [A]

1:00 – 2:00 p.m. EDT
131 Improving thyroid cancer patient outcomes, experience, and treatment decision-making.
   Susan Pitt, MD, MPHS, Endocrine Surgeon [All,SR]
132 Contemporary surgical treatment of differentiated (papillary and follicular) thyroid cancer and recurrent thyroid cancer. R. Alex Harbison, MD, MS, Endocrine Surgeon.
   [Adv,AYA,H,N,Ped,PF,SR]
133 Medullary thyroid cancer roundtable: Helping everyone understand our journey.
   Bill McClain, Bill Nelson, and Kelley Pratt, ThyCa Volunteers. [M]
134 Adjusting to and coping with thyroid cancer: What does this mean and look like for me?
   Kimberly M. Davis, PhD, Clinical Psychologist. [All,SR]
135 MTC and MEN2A/B: implications for the patient and their family.
   Ruth T. Casey, MD, Endocrinologist, Tom R. Kurzawinski, MD, Endocrine Surgeon, and Jo Grey, CEO of AMEND. [M,SR]

Session Key (You are welcome to attend any session.)

A: Anaplastic  Adv: Advanced Disease  All: All Attendees  AYA: Adolescent/Young Adult  H: Hurthle Cell
M: Medullary  N: Newly Diagnosed  Ped: Pediatric  PF: Papillary/Follicular  SR: Session to be Recorded
Friday, September 16, 2022, 2:30 – 3:30 p.m. EDT
141 Your mouth, salivary glands, and teeth: Preventing and solving issues caused by treatments, including radioactive iodine or external beam radiation.
Mark S Chambers, DMD, MS, Oral Medicine Specialist. [All,SR]

142 Overview and discussion about thyroid cancer and pregnancy.
Kaniksha Desai, MD, ECNU, Endocrinologist; and Caroline T. Nguyen, MD, Endocrinologist. [Adv,H,M,N,PF,SR]

143 Medullary thyroid cancer: What is it, and what do I do now? Understand the terms, and learn how to navigate treatment at the beginning of the journey.
Mimi I. Hu, MD, Endocrinologist. [M,SR]

144 How does thyroid cancer differ when it’s in children and teenagers, compared to adults?
Jonathan Wasserman, MD, PhD, Pediatric Endocrinologist. [Ped,SR]

145 Development of a Decision Aid for Decisions about Radioactive Iodine Therapy among Patients Diagnosed with Thyroid Cancer. Alaina Carr, PhD, Clinical Psychologist. [Adv,AYA,H,Ped,PF,SR]

4:00 – 5:00 p.m. EDT
151 Approaches for RAI therapy and RAI refractory (non-avid, RAI resistant) disease.
Mabel Ryder, MD, Endocrinologist. [Adv,H,PF,SR]

152 Patient advocacy issues in the era of pandemic and digital health.
Erik Blomain, MD, PhD, Radiation Oncologist and Patient Advocate. [All,SR]

153 Ask a doctor your questions about medullary thyroid cancer.
Mimi I. Hu, MD, Endocrinologist. [M,SR]

154 The ABCs of thyroid cancer: Understanding key terms, concepts, and initial diagnostic and treatment steps. Kaniksha Desai, MD, ECNU, Endocrinologist. [N,SR]

155 Regulating our Dysregulation: A guided relaxation session followed by a discussion offering practical tools for enhancing our quality of life.
Donna Sherman, MSW, LCSW, Behavioral Health Coach. [All,SR]

5:30 – 6:30 p.m. EDT
161 Roundtable: Connecting with community through storytelling. Participants will explore how storytelling can help us process difficult experiences and how sharing our stories can help increase our sense of connection. Participants will create their own story timelines in this session and will share a part of their story (if comfortable) with a partner during the session. In closing, participants will identify how they want to write the next chapter of their narrative.
Jessie Larson-Wu, MA, LPC, Mental Health Therapist, ThyCa’s Director of Podcasts. [All]

162 The risks of secondary cancers from radioactive iodine treatment.
Erik Blomain, MD, PhD, Radiation Oncologist & Patient Advocate. [Adv,AYA,H,N,Ped,PF,SR]

163 Medullary thyroid cancer in 2022: Considerations before, during, and after surgery.
Mark E. Zafereo, MD, Head and Neck Surgeon. [M,SR]

164 Roundtable: Learn how ThyCa serves the thyroid cancer community through Social Media and how you can be a micro-influencer. Daria Jerauld, ThyCa Director of Social Media. [All]

165 Protecting yourself and your family by planning ahead. Estate planning can be overwhelming and can often bring up topics that are difficult to discuss. However, being prepared can also bring a sense of comfort. This seminar will cover the various documents that can make up an estate plan, things to consider as you begin the process of creating your plan and options available to individuals to protect their medical decision-making rights.
Monica Fawzy Bryant, Esq, Attorney. [All,SR]
Friday, September 16, 2022, 7:00 – 8:30 p.m. EDT

171 Young adults virtual meet-up. For people ages 18 to 40. Anjali Kapoor-Davis, ThyCa Volunteer. [AYA]

172 Virtual anaplastic thyroid cancer meet-up.
   Cheri Lindle, MEd and Patti Turner, ThyCa Volunteers. [A]

173 “Meddie” (medullary thyroid cancer) virtual meet-up. Bill McClain, ThyCa Volunteer. [M]

174 Virtual papillary and follicular thyroid cancer meet-up.
   Theresa Wickerham, ThyCa Program Coordinator. [Adv,H,N,Ped,PF]

7:30 – 8:30 p.m. EDT

185 Update on trials for thyroid cancer in Australia. Bruce Robinson, MD, Endocrinologist. [A,Adv,AYA,M,PF,SR]

RECORDED SESSIONS for on-demand listening [languages noted] (more sessions may be added to this section as they become available)

500 Challenges and difficulties in pathological diagnosis of thyroid cancer. [English]
   Shoko Kure, MD, PhD, Pathologist. [All]

511 Diagnóstico e manejo do cancer de tireoide medular. [Português] Ana O. Hoff, MD, Endocrinologista. [M]

521 甲状腺结节：常识介绍。[简体中文] 关海霞，医学博士，内分泌科医生。[全部]

522 甲状腺癌的诊断。[简体中文] 王卓颖，医学博士，头颈外科医生。[全部]

523 甲状腺癌的治疗。[简体中文] 王卓颖，医学博士，头颈外科医生。[全部]

Session Key (You are welcome to attend any session.)

<table>
<thead>
<tr>
<th>A: Anaplastic</th>
<th>Adv: Advanced Disease</th>
<th>All: All Attendees</th>
<th>AYA: Adolescent/Young Adult</th>
<th>H: Hurthle Cell</th>
</tr>
</thead>
<tbody>
<tr>
<td>M: Medullary</td>
<td>N: Newly Diagnosed</td>
<td>Ped: Pediatric</td>
<td>PF: Papillary/Follicular</td>
<td>SR: Session to be Recorded</td>
</tr>
</tbody>
</table>
Saturday, September 17, 2022

• All program times are EDT (New York City time)
• Check out our online auction, www.thyca.org/auction
• Your feedback is important! Please fill out the session evaluation survey at the end of each session.

8:30 – 9:30 a.m. EDT
201 Discussion about thyroid nodules and pathological diagnosis, and types of thyroid tumors and pathological features. Zubair W. Baloch, MD, PhD, Pathologist. [Adv, AYA, H, Ped, PF, SR]
202 Ask a doctor your questions about papillary, follicular and Hurthle Cell thyroid cancers. Valentina D. Tarasova, MD, Endocrinologist. [Adv, AYA, H, N, Ped, PF, SR]
203 Helping families communicate better with each other and with their medical team, including the value of emotional intelligence and the role of behavioral styles. Cheri Lindle, MEd, ThyCa Volunteer. [All, SR]
204 Roundtable: Discussion for radioactive iodine resistant thyroid cancer survivors. How do we manage our care. Anjali Kapoor-Davis and Abby Melendez, ThyCa Volunteers. [Adv, H, PF]

10:00 – 11:00 a.m. EDT
211 Am I a candidate for a non-surgical treatment option? A discussion about percutaneous alcohol ablation, and radiofrequency ablation. Moderator: Jennifer L. Holkem, Executive Director, Save Your Thyroid. Shahzad Ahmad, MD, FACE, ECNU, Endocrinologist; and Jules Aljammal, MD, ECNU, Endocrinologist. [Adv, AYA, H, M, N, PF, SR]
213 Medullary thyroid cancer roundtable: Answering questions about Friday’s sessions. [M]
214 Discussion with a doctor about anaplastic thyroid cancer and Hurthle cell thyroid cancer. What’s new? Jochen J. Lorch, MD, MSc, Medical Oncologist. [A, Adv, H, SR]
215 Haga sus preguntas a el médico en español. Carlos S. Duque, MD, Cirujano de Cabeza y Cuello. [SR]

11:10 – 11:20 a.m. EDT
226 Welcome and announcements. Gary Bloom, ThyCa Executive Director; and Howard Solomon, ThyCa Board Member.
Saturday, September 17, 2022, 11:30 a.m. – 12:30 p.m. EDT

231 Patient decision-making in low-risk papillary thyroid cancer, including active surveillance. Louise Davies, MD, MS, FACS, Otolaryngologist; Anna Sawka, MD, PhD, Endocrinologist; and R. Michael Tuttle, MD, Endocrinologist. [AYA,N,P,PF,SR]

232 Test your cancer: Genomic cancer testing overview. Valerie Bastani, BSN, RN, OCN; Shari Bates, BSN, RN, OCN, CCM; and Valentina D. Tarasova, MD, Endocrinologist. [All,SR]

233 Medullary thyroid cancer: Locating disease and treatment options for metastases using lab results and imaging. Douglas W. Ball, MD, Endocrinologist. [M,SR]

234 Pediatric thyroid cancer roundtable: Coping, treatment options, and being part of a community of survivors. Carol DiFelice, RN, and Pam Mendenhall, LISW, ThyCa Volunteers. [Ped]

235 Haga sus preguntas a el médico en español. Esta es una continuación de la sesión 215 si se necesita más tiempo. Carlos S. Duque, MD, Cirujano de Cabeza y Cuello. [SR]

1:00 – 2:00 p.m. EDT

241 Roundtable: Discuss the low-iodine diet. Daria Jerauld and Becky Johnson, ThyCa Volunteers. [Adv,AYA,N,Ped,PF,SR]

242 I’ve had surgery followed by radioactive iodine. Now I have non-avid (RAI resistant) disease. When should I consider biomarker testing to look for NTRK, RET and other therapeutic targets? Naifa L. Busaidy, MD, Endocrinologist. [Adv,AYA,H,Ped,PF,SR]

243 Ask a doctor your questions about medullary thyroid cancer. Douglas W. Ball, MD, Endocrinologist. [M,SR]

244 Living with hypoparathyroidism which sometimes is a side effect of thyroid cancer treatment.


2:30 – 3:30 p.m. EDT

251 Targeted therapies (i.e.: multi-kinase inhibitors, RET and NTRK inhibitors) in advanced thyroid cancer. Jonathan Wadsley, MA, MRCP, FRCR, Oncologist. [Adv,AYA,H,M,N,Ped,PF,SR]

252 Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care? Naifa L. Busaidy, MD, Endocrinologist. [Adv,AYA,H,Ped,PF,SR]

253 Medullary thyroid cancer roundtable: Breakout rooms by disease status to talk after hearing from some of the doctors. Bill Nelson, Kelley Pratt, and Florence Zysman, ThyCa Volunteers. [M]

254 Monitoring of low and intermediate risk papillary and follicular thyroid cancer patients in the first five years after initial treatment(s). Sana Ghaznavi, MD, Endocrinologist. [AYA,Ped,PF,SR]

255 The use of Thyrogen® versus T4 withdrawal to prepare for radioactive iodine treatment or scans and/or for stimulated thyroglobulin testing, with or without scans. Sarimar N. Agosto Salgado, MD, Oncologic Endocrinologist. [Adv,AYA,H,N,Ped,PF,SR]

<table>
<thead>
<tr>
<th>Session Key (You are welcome to attend any session.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: Anaplastic</td>
</tr>
<tr>
<td>M: Medullary</td>
</tr>
</tbody>
</table>

25th International Thyroid Cancer Survivors’ Conference • 2022 • [www.thyca.org](http://www.thyca.org)
Saturday, September 17, 2022, 4:00 – 5:00 p.m. EDT

261 Panel discussion: Understanding thyroid hormone replacement therapy.
Francesco S. Celi, MD, Endocrinologist; Jacqueline Jonklaas, MD, PhD, MPH, Endocrinologist; and Lizzy McAninch, MD, Endocrinologist. [SR]


263 Medullary thyroid cancer roundtable: Clarifying any confusion in what we’ve learned so far this weekend.
ThyCa Volunteers. [M]

264 Thyroid Cancer and the Importance of Your Story. Filmmaker and thyroid cancer survivor, Bryn Silverman, will walk participants through her creative process and what she's learned as a patient in the making of her documentary film about her treatment. Participants will be invited to share their own experiences and thoughts on the subject. What is your story? How have you maintained/discovered/rewritten your own personal narrative since your diagnosis? Bryn Silverman, Filmmaker and Thyroid Cancer Survivor. [All,SR]

265 Roundtable: Discussion among adolescents and young adults. For people ages 18 to 40. Anjali Kapoor-Davis, ThyCa Volunteer. [AYA]

5:30 – 6:30 p.m. EDT

271 Panel discussion: Question and answer session. We will address whatever questions have come up as the meeting has progressed.
Moderator: R. Michael Tuttle, MD, Endocrinologist.
Panelists: Sarimar N. Agosto Salgado, MD, Oncologic Endocrinologist; Jennifer Choe, MD, PhD, Medical Oncology; and Avital Harari, MD, MSc, Endocrine Surgeon. [All,SR]

272 Music therapy and how it relates to supporting all that goes into a cancer diagnosis and journey. Sharon Hickox, MM, LPMT, MT-BC, CCTSI, Music Therapist. [All,SR]

273 AYA roundtable: Self-care and thyroid cancer. Bev McLaughlin, MA, Patient Navigator. [AYA]

274 Roundtable: Anaplastic thyroid cancer. Cheri Lindle, MEd; and Patti Turner, ThyCa Volunteers. [A]

Support the 21st ThyCa Auction
Go to www.thyca.org/auction and help us raise much-needed funds for thyroid cancer research. The auction ends at 9 p.m. EDT tonight.

Session Key (You are welcome to attend any session.)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Anaplastic</td>
</tr>
<tr>
<td>Adv</td>
<td>Advanced Disease</td>
</tr>
<tr>
<td>All</td>
<td>All Attendees</td>
</tr>
<tr>
<td>AYA</td>
<td>Adolescent/Young Adult</td>
</tr>
<tr>
<td>H</td>
<td>Hurthle Cell</td>
</tr>
<tr>
<td>M</td>
<td>Medullary</td>
</tr>
<tr>
<td>N</td>
<td>Newly Diagnosed</td>
</tr>
<tr>
<td>Ped</td>
<td>Pediatric</td>
</tr>
<tr>
<td>PF</td>
<td>Papillary/Follicular</td>
</tr>
<tr>
<td>SR</td>
<td>Session to be Recorded</td>
</tr>
</tbody>
</table>

25th International Thyroid Cancer Survivors’ Conference • 2022 • www.thyca.org
Sunday, September 18, 2022

- All program times are EDT (New York City time)
- Your feedback is important! Please fill out the session evaluation survey at the end of each session.

10:00 – 11:00 a.m. EDT
301 Complications from treatments and balancing benefits-risks.
   Megan R. Haymart, MD, Endocrinologist. [Adv,H,PF,SR]

   Cord Sturgeon, MD, MS, Endocrine Surgeon. [Adv,AYA,H,Ped,PF,SR]

303 Medullary thyroid cancer roundtable: Questions as we begin day 3.
   Karen Geisenberger, ThyCa Volunteer. [M]

304 ThyCa support group facilitators: current and prospective.
   Abby Melendez, Director of Support Groups; and
   Theresa Wickerham, ThyCa Program Coordinator.

305 Immunotherapy in thyroid cancer. Ann W. Gramza, MD, Oncologist. [All,SR]

11:10 – 11:20 a.m. EDT
316 Welcome and announcements.
   Gary Bloom, ThyCa Executive Director; and Howard Solomon, ThyCa Board Chair.

11:30 a.m. – 12:30 p.m. EDT
321 Controversies in the management of differentiated thyroid cancer (papillary or follicular thyroid cancer).
   Julie Ann Sosa, MD, MA, Surgeon. [N,PF,SR]

322 Hurthle cell thyroid cancers – these are NOT papillary or follicular thyroid cancers. Where is the research going in this disease and what has been done so far?
   David G. McFadden, MD, Endocrinologist. [Adv,AYA,H,SR]

323 Medullary thyroid cancer: Medical management of a chronic disease.
   Danica M. Vodopivec, MD, Oncologic Endocrinologist. [M,SR]

324 Pediatric thyroid cancer roundtable: A parent's story about NTRK and discussing the importance of tumor testing as well as the latest updates.
   Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist;
   Theodore W. Laetsch, MD, Pediatric Oncologist; and Susan Spinosa, ThyCa Volunteer. [Ped]

325 Roundtable: Conquer the fear of cancer recurrence.
   Theresa Wickerham, ThyCa Program Coordinator. [Adv,AYA,H,PF]

---

**Session Key** (You are welcome to attend any session.)

- **A**: Anaplastic
- **Adv**: Advanced Disease
- **All**: All Attendees
- **AYA**: Adolescent/Young Adult
- **H**: Hurthle Cell
- **M**: Medullary
- **N**: Newly Diagnosed
- **Ped**: Pediatric
- **PF**: Papillary/Follicular
- **SR**: Session to be Recorded
Sunday, September 18, 1:00 – 2:00 p.m. EDT
331 Surgical complications: Voice issues and other problems.
David Myssiorek, MD, FACS, Otolaryngologist. [A,Adv,AYA,H,PF,SR]
332 Systemic treatment options for radioactive iodine-refractory metastatic papillary, follicular, and hurthle cell thyroid cancer. Vineeth K. Sukrithan, MD, Medical Oncologist. [Adv,AYA,H,Ped,PF,SR]
333 Medullary thyroid cancer roundtable: Wrapping up the conference. Does anyone have any more questions? ThyCa Volunteer. [M]
334 Pediatric thyroid cancer. Ask a doctor your questions about pediatric thyroid cancer, from minimally invasive to advanced disease.
Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist. [Ped,SR]
335 Roundtable: AYA thyroid cancer and a discussion on friendships, dating, relationships, and how thyroid cancer affects them. Anjali Kapoor-Davis, ThyCa Volunteer. [AYA]
336 Haga sus preguntas a la médica en español. Amanda LaGreca, MD, Endocrinólogo. [SR]

2:30 – 3:30 p.m. EDT
342 Poorly differentiated thyroid cancer roundtable: What have we learned this weekend.
Julie Martwick, ThyCa Volunteer. [Adv,PF]
343 Precision medicine: Integrating computational analysis with clinical and genomic information to inform clinical decision-making to offer better care for thyroid cancer patients. Theodora Pappa, MD, PhD, Endocrinologist. [A,Adv,AYA,H,M,Ped,PF,SR]
344 Nonsurgical treatment options for primary PTC: Patients share their experience with radiofrequency ablation.
Ralph P. Tufano, MD, MBA, FACS, Otolaryngologist; and
Jennifer L. Holkem, Executive Director, Save Your Thyroid. [N,PF]

3:35 – 4:00 p.m. EDT
356 Conference wrap-up: Resources and next steps after the conference, your feedback on the conference, and suggestions for next year.
Gary Bloom, ThyCa Executive Director; and Theresa Wickerham, ThyCa Program Coordinator.

Thank you for attending! We hope to see you in person next year!

---

Session Key (You are welcome to attend any session.)

A: Anaplastic  Adv: Advanced Disease  All: All Attendees  AYA: Adolescent/Young Adult  H: Hurthle Cell
M: Medullary  N: Newly Diagnosed  Ped: Pediatric  PF: Papillary/Follicular  SR: Session to be Recorded